UGF3 reinspection delay
FDA reinspection for UGF3 facility is pending; timeline is uncertain (up to 8 months from September 2025), delaying injectable product launches.
AUROPHARMA / Q2-FY26 / risks
Keep the risk register visible.
Aurobindo Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Pen-G MIP policy uncertainty
Minimum import price (MIP) representation to government is pending; if delayed or denied, Pen-G ramp-up and profitability may be impacted.
Biosimilar competitive intensity
New FDA draft guidance may lower entry barriers, increasing competition; Aurobindo may be third or later entrant in key products like denosumab.
High CapEx intensity
H1 CapEx at INR 1,500 crore; ongoing investments in biosimilars, biologics CMO, and Pen-G may pressure cash flows despite unutilized capacities.